Table 2 Response to treatment
Group (n) | Treatment | Complete pathological response (pCR) | Outcome description |
|---|---|---|---|
HER2+ [9] | Paclitaxel Doxorubicin Cyclophosphamide and TZM | 55,5% | Five patients were alive with no evidence of disease recurrence; Three patients had disease recurrence; One patient deceased with disease progression (median follow-up 33.6 months) |
HER2- [11] | Paclitaxel Doxorubicin Cyclophosphamide | 18% | Four patients had systemic disease recurrence; one patient deceases with disease progression; two patients were under palliative care; seven patients lived with no evidence of disease recurrence (median follow-up 36.1 months) |